Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cinta Lleixà

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 22, 2021
Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDPLuis Querol, Cinta Lleixà
Journal of the Peripheral Nervous System : JPNS|June 5, 2023
The autoimmune vulnerability of the node of RanvierLuis Querol, Emilien Delmont, Cinta Lleixà
Current Opinion in Neurology|August 22, 2022
Autoimmune nodopathies, an emerging diagnostic categoryLorena Martín-Aguilar, Cinta Lleixà, Elba Pascual-Goñi
Frontiers in Immunology|March 31, 2023
Effect of monovalency on anti-contactin-1 IgG4Guillaume Taieb, Alexandre Jentzer, Elisa Vegezzi, et al.
Scientific Reports|August 19, 2017
Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositisNoemí De Luna, Xavier Suárez-Calvet, Cinta Lleixà, et al.
Nature Reviews. Neurology|September 5, 2025
The changing landscape of primary autoimmune neuropathiesMarta Caballero-Ávila, Elba Pascual-Goñi, Cinta Lleixà, et al.
The Journal of Clinical Investigation|March 15, 2019
Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivoConstance Manso, Luis Querol, Cinta Lleixà, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 10, 2022
IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune NodopathyAlexandre Jentzer, Arthur Attal, Clémence Roué, et al.
BMC Musculoskeletal Disorders|November 28, 2020
Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubesEsther Fernández-Simón, Cinta Lleixà, Xavier Suarez-Calvet, et al.
Neuromuscular Disorders : NMD|May 16, 2026
Sensory neuronopathy secondary to gene therapy with AT845 for Pompe diseaseLaura Pena-Guzman, Carla Bolano-Díaz, Cinta Lleixà, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 22, 2021
Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDPLuis Querol, Cinta Lleixà
Journal of the Peripheral Nervous System : JPNS|June 5, 2023
The autoimmune vulnerability of the node of RanvierLuis Querol, Emilien Delmont, Cinta Lleixà
Current Opinion in Neurology|August 22, 2022
Autoimmune nodopathies, an emerging diagnostic categoryLorena Martín-Aguilar, Cinta Lleixà, Elba Pascual-Goñi
Frontiers in Immunology|March 31, 2023
Effect of monovalency on anti-contactin-1 IgG4Guillaume Taieb, Alexandre Jentzer, Elisa Vegezzi, et al.
Scientific Reports|August 19, 2017
Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositisNoemí De Luna, Xavier Suárez-Calvet, Cinta Lleixà, et al.
Nature Reviews. Neurology|September 5, 2025
The changing landscape of primary autoimmune neuropathiesMarta Caballero-Ávila, Elba Pascual-Goñi, Cinta Lleixà, et al.
The Journal of Clinical Investigation|March 15, 2019
Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivoConstance Manso, Luis Querol, Cinta Lleixà, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 10, 2022
IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune NodopathyAlexandre Jentzer, Arthur Attal, Clémence Roué, et al.
BMC Musculoskeletal Disorders|November 28, 2020
Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubesEsther Fernández-Simón, Cinta Lleixà, Xavier Suarez-Calvet, et al.
Neuromuscular Disorders : NMD|May 16, 2026
Sensory neuronopathy secondary to gene therapy with AT845 for Pompe diseaseLaura Pena-Guzman, Carla Bolano-Díaz, Cinta Lleixà, et al.
Pageof 5